1. Home
  2. LEXX vs HHS Comparison

LEXX vs HHS Comparison

Compare LEXX & HHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEXX
  • HHS
  • Stock Information
  • Founded
  • LEXX 2004
  • HHS 1923
  • Country
  • LEXX Canada
  • HHS United States
  • Employees
  • LEXX 7
  • HHS N/A
  • Industry
  • LEXX Biotechnology: Pharmaceutical Preparations
  • HHS Advertising
  • Sector
  • LEXX Health Care
  • HHS Consumer Discretionary
  • Exchange
  • LEXX Nasdaq
  • HHS Nasdaq
  • Market Cap
  • LEXX 38.9M
  • HHS 52.3M
  • IPO Year
  • LEXX N/A
  • HHS N/A
  • Fundamental
  • Price
  • LEXX $2.23
  • HHS $5.41
  • Analyst Decision
  • LEXX Strong Buy
  • HHS
  • Analyst Count
  • LEXX 2
  • HHS 0
  • Target Price
  • LEXX $11.00
  • HHS N/A
  • AVG Volume (30 Days)
  • LEXX 202.4K
  • HHS 22.7K
  • Earning Date
  • LEXX 01-10-2025
  • HHS 11-14-2024
  • Dividend Yield
  • LEXX N/A
  • HHS N/A
  • EPS Growth
  • LEXX N/A
  • HHS N/A
  • EPS
  • LEXX N/A
  • HHS N/A
  • Revenue
  • LEXX $464,278.00
  • HHS $187,604,000.00
  • Revenue This Year
  • LEXX $20.39
  • HHS N/A
  • Revenue Next Year
  • LEXX $113.25
  • HHS $4.05
  • P/E Ratio
  • LEXX N/A
  • HHS N/A
  • Revenue Growth
  • LEXX 105.24
  • HHS N/A
  • 52 Week Low
  • LEXX $1.20
  • HHS $5.31
  • 52 Week High
  • LEXX $6.85
  • HHS $8.87
  • Technical
  • Relative Strength Index (RSI)
  • LEXX 47.23
  • HHS 33.68
  • Support Level
  • LEXX $2.00
  • HHS $5.73
  • Resistance Level
  • LEXX $2.54
  • HHS $5.98
  • Average True Range (ATR)
  • LEXX 0.24
  • HHS 0.27
  • MACD
  • LEXX -0.00
  • HHS 0.01
  • Stochastic Oscillator
  • LEXX 27.06
  • HHS 11.24

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

About HHS Harte-Hanks Inc.

Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.

Share on Social Networks: